Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Medical genetics wikipedia , lookup
Cancer epigenetics wikipedia , lookup
Biology and consumer behaviour wikipedia , lookup
Pathogenomics wikipedia , lookup
Mir-92 microRNA precursor family wikipedia , lookup
BRCA mutation wikipedia , lookup
Genome (book) wikipedia , lookup
14M Genomics Website About 14M Genomics & Our Mission About 14M Genomics 14M Genomics is a new cancer diagnostic company, based in Cambridge UK and working in partnership with the Wellcome Trust Sanger Institute, to enrich the understanding of the role of cancer genes in the biology of disease. We employ state-of-the-art sequencing and analytical tools, coupled with an in-depth understanding of cancer biology, to reveal associations between tumour genomics and the clinical path of the individual patients. Our processes will generate linked genomic and clinical datasets that will provide a reference enabling the diagnostic and prognostic stratification of patients and ultimately guide treatment options for the oncologist and patient alike. Our mission To become the European Leader in the provision of clinical genomics services and decision support tools, that inform the diagnosis, prognosis and treatment of cancer. We aim to work together with the oncology community, pharmaceutical partners and academic institutes to improve the lives of cancer patients. Cancer Biology/Our Approach Globally, there are 14 million new cancer diagnoses a year, highlighting the need for better treatments in this field. Changes to our cellular DNA during life, result in genetic alterations known as somatic mutations or variants. These changes can initiate and drive the emergence and progression of tumours. Research performed by our founders, at the Sanger Institute Cancer Genome Project and other leading centres, has identified many of the causal, disease-driving genetic changes and demonstrated the significant role that genetics plays in cancer biology. We are working in collaboration with the Sanger Institute and leading clinical research centres to determine the role of somatic variants in cancer genes in both solid and liquid tumours. This knowledge will enable us to develop clinical diagnotstic tools to improve the diagnosis, treatment and outcomes of patients affected by these diseases. Our Team Founders Professor Sir Michael Stratton PhD, FRS Mike Stratton is Director of the Wellcome Trust Sanger Institute. He qualified in medicine at Oxford University and Guy’s Hospital, trained as a histopathologist and obtained a PhD in the molecular biology of cancer at the Institute of Cancer Research, London. His primary research interests have been in the genetics of cancer. His early research focused on inherited susceptibility. He mapped and identified the major high risk breast cancer susceptibility gene BRCA2 and subsequently a series of moderate risk breast cancer and other cancer susceptibility genes. In 2000 he initiated the Cancer Genome Project at the Wellcome Trust Sanger Institute which conducts systematic genome-wide searches for somatic mutations in human cancer. Through these studies he discovered somatic mutations of the BRAF gene in malignant melanoma and several other mutated cancer genes in lung, renal, breast and other cancers. He has described the basic patterns of somatic mutation in cancer genomes revealing underlying DNA mutational and repair processes. He is a Fellow of the Royal Society (FRS) and was knighted by the Queen in 2013. Peter Campbell MD, PhD Peter Campbell is Head of Cancer Genetics and Genomics at the Wellcome Trust Sanger Institute, having started a Wellcome Trust Senior Clinical Fellowship in 2010. He completed specialist training in Haematology in 2002. Following this, he completed a PhD at the University of Cambridge in the molecular pathogenesis and clinical management of myeloproliferative disorders. Since 2007, Dr Campbell has been employed at the Cancer Genome Project, Wellcome Trust Sanger Institute. In 2010, he was awarded the CR-UK Future Leaders in Cancer Research Prize. His major interest is cancer genomics, and his recent research has been concentrated on the implementation of next generation sequencing technologies for the detection of somatically acquired genetic variants in tumour samples. One major aspiration is to develop translational applications of high-throughput genomic screening for the care of patients with cancer. Ultan McDermott MD, PhD Ultan McDermott is a clinician scientist with an interest in cancer genomes and how they impact on drug response in the clinic. He is a Group Leader in the Wellcome Trust Sanger Institute as well as a practicing Oncologist at Addenbrooke's Hospital in Cambridge. He trained as a medical oncologist and obtained a PhD in cancer biology at Queen's University, Belfast. He was accepted for a post-doctoral research position at Harvard Medical School and Massachusetts General Hospital in 2005, where he established a high-throughput cancer cell line drug screen to identify genomic alterations that could be used in the clinic to stratify patients for treatment. He joined the Sanger Institute in 2009 as a clinical research fellow and was appointed to the faculty as a junior Group Leader in 2010 with the award of a Cancer Research UK fellowship. He was made a Fellow of the Royal College of Physicians in 2011. Leadership Team Andrew Sandham, Chairman & Acting CEO Andrew is a Partner of Syncona Partners LLP. Previously he was a co-founder, Chairman and CEO of Kymab. He has played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals. He has also served as non-executive Chairman of Syntaxin and Novacta Biosystems, non-executive director of Synosia and was a venture partner with Abingworth LLP. Andrew is currently also Chairman of Bicycle Therapeutics, a nonexecutive director of PBL and serves on the Cambridge Enterprise Seed Funds Investment Committee. He holds a degree in Chemistry from University of East Anglia and a Diploma in Marketing from Chartered Institute of Marketing. Dr Philip Beer, Director of Medical Genomics Philip studied medicine at the University of Nottingham, and undertook his specialist training in haematology at the Imperial College hospitals, London. He was awarded a PhD by Queens' College Cambridge in 2009, based on work with Tony Green's group investigating genotype-phenotype correlations in haematological cancers. Following a year as a Clinical Lecturer in Cambridge, Philip spent 4 years with the group of Connie Eaves at the Terry Fox Laboratory in Vancouver, Canada. His research during this period was focussed on understanding how leukaemia is initiated and propagated in human blood cells Collaborations 14MGs aim is to build clinical genomics services and decision support tools across the major tumour sites. For this we need to work with the best clinical groups in the UK and Europe. We are seeking academic and pharmaceutical company collaborators with access to clinical studies in the major haematological and solid cancers, where consent is in place for conduct of genomic analysis. We work with our collaborators to generate linked diagnostic and outcomes clinical data with underlying genetic drivers of disease, to serve as reference tools for at-diagnosis prognostic and treatment decision guidance. Investors 14M Genomics is a spin-out of the Wellcome Trust Sanger Institute. The company is financed through an equity investment of Syncona Partners, an evergreen investment company that is an independent subsidiary of the Wellcome Trust. Syncona Partners was founded in 2012 with an initial £200m capitalisation and committed a £12 million Series A financing of 14M Genomics in October 2014. Syncona Partners has the resources and vision to support the 14M Genomic board and management in building a substantial long term European cancer genomics diagnostic business. News Series A fundraising (wording from press release) Careers We provide extraordinary career opportunities for talented individuals, who will have the opportunity to work with highly experienced leaders in science and business with proven track records in building successful genomic and diagnostic businesses. Our success depends on the quality, experience and ambition of the individuals that join our team. Current opportunities We are seeking talented cancer scientists, bioinformaticians and a biostatistician to join our start-up team. If you do not see a suitable position for your skills and experience today, please check back again soon. We have the financial resources and projected growth that will mean rapid expansion as we build our biopharmaceutical research and development capability. Life at 14M Genomics At 14M Genomics, you will enjoy a flexible and dynamic working environment that fosters creativity, leadership and teamwork. We offer benefits that include: competitive salaries performance-related bonuses generous stock options excellent medical cover life insurance 14M Genomics is an equal opportunity employer committed to a culturally diverse team. Our Location 14M Genomics is located on the attractive Wellcome Trust Genome Campus near Cambridge. The Campus is close to other leading academic institutions: The University of Cambridge Addenbrooke’s Hospital The Babraham Research Campus The MRC Laboratory of Molecular Biology If you are interested in a career in the clinical applications of cancer genomics please contact us at [email protected]. Contacts Feel free to contact us using the following details:Paula Barnes, Office Manager [email protected] 14M Genomics Ltd Wellcome Trust Genome Campus Hinxton Cambridge CB10 1SA